US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
biotech · Glaucoma · Hepatocellular Carcinoma · AEON
AEON Biopharma
AEON Biopharma drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
irvine, USA HQ
11 Employees
Public company Type
AEON · NYSE Ticker
Company details
- Status
- Public
- HQ
- irvine, USA
- Employees
- 11
- Programs
- 9
- Drugs
- 8
- Patents
- 9
AEON Biopharma pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
AEON Biopharma drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
atropine sulfate
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
Development asset linked to AEON Biopharma in public FDA and regional records.
-
Development asset linked to AEON Biopharma in public FDA and regional records.
-
Development asset linked to AEON Biopharma in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved.
-
Development asset linked to AEON Biopharma in public FDA and regional records.